Ventas, Inc.
VTR
$89.99
-0.50%
Ventas, Inc. is a healthcare-focused real estate investment trust that owns a diversified portfolio of roughly 1,400 in-place properties spanning senior housing, medical office, hospital, life science, and skilled nursing/post-acute care assets, with nearly 100 properties in Canada and the United Kingdom and a small mortgage/loan book contributing about 1% of net operating income. As one of the largest publicly traded healthcare REITs, Ventas is a scaled platform landlord whose distinct identity rests on its senior housing operating (SHOP) portfolio, which now generates the overwhelming majority of revenue and ties the company's fortunes directly to occupancy recovery, rent growth, and operator performance rather than pure triple-net leasing. The current investor narrative centers on the senior housing recovery cycle: revenue has accelerated sharply, with Q1 2026 revenue of $1.66 billion up 22.0% year over year, and management has been aggressively recycling capital into new investments while the balance sheet carries meaningful leverage. Debate among investors hinges on whether the SHOP-driven growth is durable enough to justify a premium valuation, particularly after a strong 12-month run in the shares and a recent Barclays downgrade to Equal Weight that flagged valuation and execution risk.…
VTR
Ventas, Inc.
$89.99
Related headlines
Investment Opinion: Should I buy VTR Today?
The synthesized recommendation is Hold, with a bias toward accumulating on weakness. The core thesis is that Ventas offers direct exposure to the senior housing recovery with 22% revenue growth and a consensus buy rating, but the current valuation of 140.7x trailing PE and 21.3x EV/EBITDA already prices in much of the recovery, leaving limited margin of safety. The average analyst target of $101.86 implies 13.2% upside, but the recent Barclays downgrade and negative free cash flow warrant caution.
Supporting evidence includes the 22.0% year-over-year revenue growth in Q1 2026, a 44.1% EBITDA margin, and a PEG ratio of 0.80 that suggests growth-adjusted valuation is reasonable. The consensus recommendation mean of 1.61 (buy) and 22 analysts covering the stock provide confidence, while the 2.44% dividend yield offers some income. However, free cash flow is negative $576.9 million in Q1 2026, and the payout ratio of 3.42x on EPS indicates the dividend is not covered by earnings. The stock trades at a premium to peers on price-to-book (2.81x) and price-to-sales (6.04x), and the 6-month relative strength of -11.4% versus SPY shows momentum has faded.
The biggest risks that could invalidate the thesis are a slowdown in SHOP revenue growth, a rise in interest expense, and further analyst downgrades. This Hold would upgrade to Buy if the stock pulls back to the $80-$82 support zone (implying a more reasonable valuation) or if forward EPS estimates are raised, compressing the forward PE below 100x. It would downgrade to Sell if revenue growth decelerates below 10% or if free cash flow remains negative for multiple quarters. Relative to its history and peers, Ventas appears overvalued on most metrics, but the growth profile justifies a premium; the stock is fairly valued to slightly overvalued at current levels.
Sign up to view all
VTR 12-Month Price Forecast
Ventas presents a balanced risk/reward profile: the senior housing recovery is real and driving strong revenue growth, but the valuation already reflects much of the optimism. The stock's low beta and defensive characteristics make it suitable for income-oriented investors, but the negative free cash flow and high payout ratio raise questions about dividend sustainability. Analyst sentiment is positive but not euphoric, and the recent Barclays downgrade suggests limited near-term catalysts. I would upgrade to bullish if the stock pulls back to the $80-$82 support zone or if forward EPS estimates are raised, and downgrade to bearish if revenue growth decelerates below 10% or if free cash flow remains negative for multiple quarters.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Ventas, Inc.'s 12-month outlook, with a consensus price target around $101.86 and implied upside of +13.2% versus the current price.
Average Target
$101.86
0 analysts
Implied Upside
+13.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$90 - $113
Analyst target range
Coverage is robust, with 22 analysts following Ventas and a consensus recommendation of "buy" (recommendation mean of 1.61 on a 1-5 scale where 1 is Strong Buy). The average price target of $101.86 implies roughly 13.2% upside from the current price of $89.99, and the consensus EPS estimate of $1.94 for the forward period underpins the 113.9x forward PE. Sentiment is moderately bullish but not euphoric, with the consensus target only about 1.2% above the 52-week high of $101.60, suggesting analysts see limited near-term upside beyond a full recovery to prior highs.
The target range is relatively wide, from a low of $90.00 (essentially the current price, implying zero upside) to a high of $113.00 (25.6% upside), a spread of $23 or about 25.6% of the average target, which signals meaningful disagreement about the pace of the senior housing recovery. The high target likely assumes continued double-digit revenue growth, SHOP margin expansion, and multiple expansion toward premium REIT levels, while the low target appears to price in flat occupancy, persistent interest expense pressure, and no multiple re-rating. Institutional ratings show a mixed recent pattern: Barclays downgraded to Equal Weight from Overweight on July 7, 2026, while Evercore ISI, Wells Fargo, Jefferies, JP Morgan, KeyBanc, and RBC Capital maintain Outperform/Buy/Overweight ratings, and Scotiabank and UBS remain neutral. The downgrade by a major bank, combined with the stock's 10% pullback from its July high, suggests the market is digesting the strong run and that further gains will require tangible evidence of sustained SHOP growth rather than multiple expansion alone.
Bulls vs Bears: VTR Investment Factors
The bull case rests on Ventas' direct leverage to the senior housing recovery, evidenced by 22% revenue growth and a 44% EBITDA margin, supported by a consensus buy rating and 13.2% upside to the average analyst target. The bear case centers on extreme valuation multiples (140.7x trailing PE, 21.3x EV/EBITDA), negative free cash flow, and a recent Barclays downgrade that highlights execution risk after a strong run. Currently, the bear evidence carries slightly more weight because the stock trades at a premium to historical and sector averages while free cash flow is negative and the dividend is not covered by earnings. The single most important tension is whether SHOP-driven revenue growth can be sustained at double-digit rates to justify the premium multiple; if growth decelerates, multiple compression could be severe. Conversely, if occupancy and pricing continue to accelerate, the forward EPS inflection could validate the valuation and drive the stock toward the high target of $113.
Bullish
- SHOP-driven revenue acceleration: Q1 2026 revenue of $1.657 billion grew 22.0% year over year, with the senior housing operating portfolio contributing $1.293 billion, or roughly 79% of segment revenue. This direct leverage to the senior housing occupancy and pricing recovery is driving the strongest top-line growth Ventas has posted in years.
- Attractive PEG ratio of 0.80: Despite a trailing PE of 140.7x, the PEG ratio of 0.80 indicates the growth-adjusted valuation is reasonable if forward EPS estimates materialize. Forward EPS of $1.94 represents a dramatic inflection from the trailing $0.0071, and the PEG below 1.0 suggests the market is not overpaying for that growth.
- Analyst consensus buy with 13.2% upside: 22 analysts cover Ventas with a consensus recommendation of 'buy' (mean 1.61) and an average price target of $101.86, implying 13.2% upside from the current $89.99. The high target of $113 offers 25.6% upside, and the consensus target sits just 1.2% above the 52-week high, suggesting analysts see a full recovery as achievable.
- Low beta and orderly pullback: With a beta of 0.724, Ventas is roughly 28% less volatile than the broader market, and the maximum drawdown over the past year was only 13.5%. The stock is up 29.6% over 12 months versus SPY's 16.2%, delivering 13.4 percentage points of relative strength while maintaining defensive characteristics.
Bearish
- Extreme PE and EV/EBITDA multiples: The trailing PE of 140.7x and EV/EBITDA of 21.3x are rich for a healthcare REIT, leaving little room for execution error. Even the forward PE of 113.9x is elevated, and the 2.81x price-to-book is near the top of its multi-year range (1.55x in Q3 2022 to 2.97x in Q1 2026).
- Negative free cash flow and dividend coverage: Q1 2026 free cash flow was negative $576.9 million due to $971.5 million of capital expenditures and investment purchases, funded partly by $812.6 million of common stock issuance. The dividend payout ratio of 3.42x on EPS means reported earnings do not cover the distribution, relying on cash flow and asset sales.
- Barclays downgrade and decelerating momentum: Barclays downgraded Ventas to Equal Weight from Overweight on July 7, 2026, flagging valuation and execution risk. The stock has pulled back roughly 10% from its July high of $100.53, and the 6-month change of just 3.96% lags SPY's 15.40% by 11.4 percentage points, indicating momentum has stalled.
- High leverage and interest expense burden: Debt-to-equity of 1.055 and a debt ratio of 0.460 reflect meaningful leverage, while interest expense of $156.1 million in Q1 2026 consumes a large portion of operating income of $191.6 million. Any rise in interest rates or refinancing at higher yields would pressure net income and FFO.
VTR Technical Analysis
Ventas is in a sustained uptrend, with the shares up 29.58% over the past year versus a 16.22% gain for SPY, delivering 13.36 percentage points of relative strength. At the current price of $89.99, the stock sits at roughly 67% of its 52-week range (52-week low of $66.54, high of $101.60), meaning it has given back a portion of its earlier highs but remains comfortably in the upper half of its annual band. That positioning suggests a stock in a healthy uptrend that is consolidating rather than one that is either overextended at the highs or broken down at the lows. The 13.5% maximum drawdown over the period confirms the pullback has been orderly rather than disorderly.
Short-term momentum is positive but decelerating: the stock is up 1.10% over the past month and 6.37% over three months, both ahead of SPY's -1.06% and 3.04% respective returns, yielding relative strength of 2.16 and 3.33. However, the 6-month change of just 3.96% lags SPY's 15.40% by a wide margin (relative strength of -11.44), revealing that most of Ventas' outperformance was front-loaded in the first half of the period and that the stock has essentially moved sideways since spring. The 1-month gain of 1.10% against a 1-year gain of 29.58% signals a maturing trend rather than a reversal, with the recent drift from the July high of $100.53 to the current $89.99 representing a roughly 10% pullback from the peak. Volume of about 3.8 million shares and a short ratio of 6.69 days suggest no aggressive bearish positioning, but also no urgent accumulation.
Key technical levels are well defined: support sits near the 52-week low of $66.54, with intermediate support around the $80-$82 zone where the stock repeatedly found buyers in June, while resistance is anchored at the 52-week high of $101.60 and the July peak of $100.53. A breakout above $101.60 would confirm a resumption of the primary uptrend and likely open the door to the analyst high target of $113, whereas a breakdown below $80 would threaten the year-long uptrend structure and put the $66.54 low in play. With a beta of 0.724, Ventas is roughly 28% less volatile than the broader market, which supports larger position sizing for risk-adjusted exposure but also means the stock will likely lag in sharp risk-on rallies; the 52-week range of $66.54-$101.60 represents a 52.7% spread, underscoring that even low-beta REITs carry meaningful idiosyncratic risk.
Beta
0.72
0.72x market volatility
Max Drawdown
-13.5%
Largest decline past year
52-Week Range
$67-$102
Price range past year
Annual Return
+29.6%
Cumulative gain past year
| Period | VTR Return | S&P 500 |
|---|---|---|
| 1m | +1.1% | -1.6% |
| 3m | +6.4% | +1.3% |
| 6m | +4.0% | +13.9% |
| 1y | +29.6% | +16.3% |
| ytd | +16.4% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VTR Fundamental Analysis
Ventas' revenue trajectory is clearly accelerating: Q1 2026 revenue of $1.657 billion grew 22.01% year over year from $1.358 billion in Q1 2025, capping a string of sequential increases from $1.421 billion in Q2 2025, $1.489 billion in Q3 2025, and $1.566 billion in Q4 2025. The senior housing operating portfolio is the engine, contributing $1.293 billion of segment revenue versus $230.9 million from outpatient medical/research and $123.1 million from triple-net leased properties, meaning SHOP now accounts for roughly 79% of disclosed segment revenue. This concentration is a double-edged sword: it gives Ventas direct exposure to the powerful senior housing occupancy and pricing recovery, but it also makes results highly sensitive to labor costs and operator performance, and the 22% growth rate is flattered by comparison against a weaker prior-year base.
Profitability is thin but improving at the net level: Q1 2026 net income was $55.9 million on a 3.37% net margin, up from $46.9 million and a 3.45% margin in Q1 2025, while gross profit of $655.4 million produced a 39.56% gross margin. The reported gross margin of -5.90% in the valuation data reflects a Q4 2025 accounting distortion (gross profit of -$2.13 billion in that quarter), so the cleaner quarterly gross margins of roughly 39.6%-42.4% across recent periods are the better guide. Operating margin of 14.17% and EBITDA of $730.2 million in Q1 2026 (a 44.07% EBITDA margin) show the underlying property-level economics are solid, but heavy interest expense of $156.1 million and depreciation of $382.5 million consume most of operating income, leaving net income modest relative to the asset base.
The balance sheet carries meaningful but manageable leverage: debt-to-equity of 1.055 and a debt ratio of 0.460 reflect a capital structure typical of a large-cap REIT, while the current ratio of 0.955 indicates slightly negative working capital that is normal for the sector. Free cash flow is the key concern: TTM free cash flow is $477.4 million, but Q1 2026 free cash flow was negative $576.9 million due to $971.5 million of capital expenditures and investment purchases, funded partly by $812.6 million of common stock issuance. ROE of just 2.01% and ROA of 2.17% are low in absolute terms, though the dividend yield of 2.44% and payout ratio of 3.42x (on EPS) highlight that reported earnings do not cover the distribution, meaning the dividend relies on cash flow and asset sales rather than net income.
Quarterly Revenue
$1.7B
2026-03
Revenue YoY Growth
+22.0%
YoY Comparison
Gross Margin
39.6%
Latest Quarter
Free Cash Flow
$477428000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VTR Overvalued?
Because Ventas is profitable on a net income basis (Q1 2026 net income of $55.9 million), the PE ratio is the appropriate primary metric, but it must be interpreted with caution: the trailing PE of 140.7x reflects a tiny EPS base of $0.0071, while the forward PE of 113.9x is based on estimated EPS of $1.94. The enormous gap between trailing and forward PE implies the market expects a dramatic earnings inflection, with forward EPS roughly 270x the trailing figure, which is consistent with a REIT whose GAAP earnings are suppressed by depreciation and interest costs but whose cash flow and EBITDA are far more robust. For REITs, EV/EBITDA of 21.3x and price-to-FFO-style metrics are more meaningful than PE, and the 21.3x EV/EBITDA multiple is rich for a healthcare REIT.
Relative to the sector, Ventas trades at a premium on most metrics: its price-to-book of 2.81x, price-to-sales of 6.04x, and EV/sales of 9.30x sit above typical healthcare REIT averages, while the 2.44% dividend yield is below the 4%-5% range common among net-lease and diversified healthcare REITs. The premium is partially justified by Ventas' superior growth profile (22% revenue growth versus the low-single-digit growth typical of triple-net peers) and its direct leverage to the senior housing recovery, but the 140.7x trailing PE and 21.3x EV/EBITDA leave little room for execution error. The PEG ratio of 0.80 is the one metric that screens attractively, suggesting the growth-adjusted valuation is not stretched if the forward EPS estimates materialize.
Historically, Ventas' valuation has been volatile: PE ranged from negative readings in 2022-2023 loss periods to 345.5x in Q3 2024 and 170.4x in Q1 2026, while price-to-book has ranged from 1.55x in Q3 2022 to 2.97x in Q1 2026. The current 2.81x P/B is near the top of its multi-year band, and the 6.04x P/S is above the 2022-2024 range of roughly 14x-24x on a quarterly basis (though those figures reflect different share counts and periods). The stock is therefore priced for continued execution on the senior housing recovery, and any slowdown in occupancy growth or rise in interest expense would likely compress these multiples toward their historical midpoints.
PE
140.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 45x~346x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.3x
Enterprise Value Multiple
Investment Risk Disclosure
Ventas faces significant financial and operational risks stemming from its leveraged balance sheet and negative free cash flow. Debt-to-equity of 1.055 and a debt ratio of 0.460 are typical for a large-cap REIT but leave limited flexibility if credit conditions tighten. Q1 2026 free cash flow was negative $576.9 million, driven by $971.5 million of capital expenditures and investment purchases, and the dividend payout ratio of 3.42x on EPS means the distribution is not covered by net income, relying instead on cash flow and asset sales. Additionally, the SHOP portfolio now generates roughly 79% of segment revenue, concentrating risk in senior housing occupancy, labor costs, and operator performance; any downturn in these factors would disproportionately impact results.
Market and competitive risks include valuation compression and sector rotation. Ventas trades at a trailing PE of 140.7x, a forward PE of 113.9x, and an EV/EBITDA of 21.3x, all rich relative to healthcare REIT peers and its own history. The price-to-book of 2.81x is near the top of its multi-year range (1.55x to 2.97x), and the 2.44% dividend yield is below the 4%-5% typical of net-lease peers, offering little income support. The Barclays downgrade to Equal Weight on July 7, 2026, citing valuation and execution risk, highlights growing analyst caution. With a beta of 0.724, Ventas is less volatile than the market, but it will still be sensitive to interest rate movements and macro shifts that affect REIT valuations.
The worst-case scenario would involve a combination of slowing senior housing occupancy, rising labor costs, and higher interest rates, leading to multiple compression and earnings misses. In this scenario, the stock could retest its 52-week low of $66.54, representing a 26.1% decline from the current price of $89.99. The analyst low target of $90.00 offers essentially no downside protection, and if the company fails to meet forward EPS estimates, the forward PE could contract toward historical midpoints, implying a price in the $70s. A more severe downturn, such as a recession that pressures operator margins and delays the recovery, could push the stock below $66.54, but that would require a significant deterioration in fundamentals. From the current price, investors could lose 26% to the 52-week low in a bear case, and potentially more if the low is breached.
FAQ
The key risks include: 1) Financial risk: negative free cash flow of $576.9 million in Q1 2026 and a dividend payout ratio of 3.42x on EPS, meaning the dividend is not covered by earnings. 2) Valuation risk: trailing PE of 140.7x and EV/EBITDA of 21.3x leave little room for error, and the stock trades at a premium to peers. 3) Operational risk: SHOP accounts for 79% of segment revenue, concentrating exposure to senior housing occupancy, labor costs, and operator performance. 4) Macro risk: with a beta of 0.724, the stock is less volatile but still sensitive to interest rate movements; rising rates would increase interest expense and pressure valuations. These risks are ranked from highest to lowest severity, with financial and valuation risks being the most immediate.
The 12-month forecast includes three scenarios: bull case (25% probability) with a target range of $113-$120, driven by accelerating occupancy and EPS beats; base case (55% probability) with a target range of $98-$105, assuming steady execution and revenue growth above 15%; and bear case (20% probability) with a target range of $66-$80, triggered by a slowdown in senior housing recovery and multiple compression. The base case is most likely, with the key assumption that SHOP revenue growth remains above 15% and forward EPS meets the $1.94 consensus. The average analyst target of $101.86 aligns with the base case, implying 13.2% upside from the current price of $89.99.
VTR appears overvalued on most traditional metrics: trailing PE of 140.7x, forward PE of 113.9x, price-to-book of 2.81x, and EV/EBITDA of 21.3x are all above typical healthcare REIT averages. The dividend yield of 2.44% is below the 4%-5% range common among net-lease peers, indicating a premium valuation. However, the PEG ratio of 0.80 suggests the growth-adjusted valuation is reasonable if forward EPS estimates materialize. The market is pricing in a dramatic earnings inflection, with forward EPS of $1.94 versus trailing EPS of $0.0071. If the company delivers on growth, the valuation could be justified; otherwise, multiple compression could occur.
VTR is a good buy for long-term investors seeking exposure to the senior housing recovery, but the current valuation of 140.7x trailing PE and 21.3x EV/EBITDA leaves little margin of safety. The stock offers 13.2% upside to the average analyst target of $101.86, but the recent Barclays downgrade and negative free cash flow of $576.9 million in Q1 2026 suggest caution. The biggest downside risk is a retest of the 52-week low of $66.54, representing a 26% decline. For risk-averse investors, waiting for a pullback to the $80-$82 support zone would provide a better entry point. Overall, it is a good buy for those with a high risk tolerance and a 3-5 year horizon, but not for short-term traders.
VTR is more suitable for long-term investment (minimum 3-5 years) due to its growth stage, low beta of 0.724, and the nature of the senior housing recovery cycle, which plays out over multiple years. The dividend yield of 2.44% is modest but provides some income, though the payout ratio of 3.42x on EPS raises questions about sustainability. Earnings visibility is improving but still dependent on occupancy trends and operator performance, making short-term trading risky. The stock's 13.5% maximum drawdown over the past year shows it can be volatile, so short-term traders may find opportunities but with higher risk. A long-term holding period allows investors to benefit from the compounding effect of the senior housing recovery and potential multiple expansion.